Hjem › Diffust stort B-cellelymfom › Pennsylvania › Philadelphia
Kliniske studier for Diffust stort B-cellelymfom i Philadelphia, PA
15 studier for Diffust stort B-cellelymfom søker deltakere på steder i og rundt Philadelphia (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RekruttererFase 2
- Fox Chase Cancer Center, Philadelphia
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruttererObservasjonsstudie
- Children's Hospital of Philadelphia, Philadelphia
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RekruttererFase 2
- Thomas Jefferson University Hospital, Philadelphia
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
RekruttererFase 2/3
- Alliance Cancer Specialists (ACS) ( Site 8001), Horsham · 16 mi unna
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RekruttererFase 2
- Abramson Cancer Center and Perelman Center for Advanced Medicine ( Site 0131), Philadelphia
- Temple University Hospital ( Site 0133), Philadelphia
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
- University of Pennsylvania Abramson Cancer Center, Philadelphia
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RekruttererFase 1/2
- Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RekruttererFase 1/2
- Thomas Jefferson University, Philadelphia
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RekruttererFase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RekruttererFase 1
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RekruttererFase 1
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
RekruttererFase 1
- Abramson Cancer Center, University of Pennsylvania, Philadelphia
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
RekruttererFase 2
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia
SynKIR-310 for Relapsed/Refractory B-NHL
RekruttererFase 1
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
RekruttererFase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Diffust stort B-cellelymfom-studier i andre byer
- New York City, NY21 studier
- Baldwin Park, CA19 studier
- Chicago, IL18 studier
- Houston, TX17 studier
- Los Angeles, CA17 studier
- Boston, MA16 studier
- Milwaukee, WI16 studier
- Nashville, TN15 studier
- Portland, OR15 studier
- Durham, NC14 studier
- Dallas, TX13 studier
- Seattle, WA12 studier
Andre studier i Philadelphia
- Kreft (alle typer)59 studier
- Brystkreft56 studier
- Ikke-småcellet lungekreft51 studier
- Metastatisk kreft46 studier
- Kolorektal kreft44 studier
- Eggstokkreft44 studier
- Prostatakreft44 studier
- Lungekreft36 studier
- Akut myelogen leukemi34 studier
- Hjertesvikt31 studier
- Endometriekreft28 studier
- Depresjon26 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.